Compare Nano Dimension Ltd - ADR (NNDM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Nano Dimension Ltd - ADR trades at $1.67 (market cap $350.49M), while Vertex Pharmaceuticals Incorporated trades at $528.26 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 383× Nano Dimension Ltd - ADR's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| NNDM | VRTX | |
|---|---|---|
Market Cap | $350.49M | $134.25B |
Sector | Technology | Health |
52-Week High | $2.14 | $529.65 |
52-Week Low | $1.21 | $376.62 |
Enterprise Value | -$54.35M | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.67, up 2.45% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $121 million with a net loss of $163 million, reflecting a negative net margin of -135.18%. Recent strategic actions include selling non-core assets to reduce cash burn and appointing an interim CEO amid board restructuring.
The outlook remains challenged by persistent losses and high cash burn, though asset sales may improve liquidity. Investment opportunity hinges on successful execution of cost-saving initiatives and strategic refocusing. Key risks include ongoing operational losses, leadership transitions, and competitive pressures in the additive manufacturing sector.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
